Pharmacyclics Announces Oral Presentations and Clinical Update at Upcoming Medical Meetings

Thursday, May 19, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

Oral Abstract Data Presentation at ASCO, Chicago (June 3 – 7, 2011)

Abstract #6508

Title: Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (CLL/SLL): Interim results of a Phase Ib/II study. J.C. Byrd et al.

Date/Time: Monday, June 6, 2011; Oral Abstract Session: 9:30 AM – 12:30 PM

Session Title: Leukemia, Myelodysplasia and Transplantation

Location: Arie Crown Theater

Oral Abstract Data Presentations at ICML, Lugano, Switzerland (June 15-18, 2011)

Abstract # 122

Title: The Btk Inhibitor PCI-32765 is Highly Active and Tolerable in Patients with Poor-Risk CLL: Interim Results from a Phase Ib/II Study.  S. O'Brien et al.

Date/Time: Friday, June 17, 2011; 9:45 AM

Session 10: Chronic Lymphocytic Leukemia (CLL)

Location: Room A, B, C and Marquee Parco Ciani)

Abstract # 153

Title: The Btk inhibitor PCI-32765 is highly active and well tolerated in patients (pts) with relapsed/refractory B-cell malignancies: Final results from a Phase Ia study.  R.H. Advani et al.

Date/Time: Saturday, June 18, 2011; 9:30 AM

Session 14:  Signaling Pathways in Lymphoma

Location: Room A



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook